application) This is the second competing renewal application for a training program in Pediatric Nephrology under the leadership of Dr. Michel G. Baum, who will be the Program Director and is also the Director of the Division of Pediatric Nephrology. The purpose of the training program in Pediatric Nephrology at the University of Texas Southwestern Medical Center is to train pediatricians for careers as independent investigators in academic Pediatric Nephrology. There is a shortage of Pediatric Nephrologists in the United States and many positions in Pediatric Nephrology go unfilled each year. Most trainees in Pediatric Nephrology do not receive training to prepare them for independent research careers. This application requests funds for two Pediatric Nephrology fellowship positions (clinical training is paid by the Department of Pediatrics). Fellows will spend at least two years in clinical or basic research related to renal development, renal physiology, metabolic bone disease and the pathophysiology of kidney disease in children. In addition, fellows attend weekly conferences given by the Department of Pediatrics designed to prepare fellows for careers in academic medicine. Topics related to ethics in medicine and biomedical research are strongly emphasized in these lectures and the University of Texas Southwestern Medical Center also gives additional medical ethics lectures for fellows and faculty. Joint weekly conferences by the Divisions of Pediatric and Internal Medicine Nephrology include clinical and molecular biology journal clubs, renal grand rounds, renal research conference, and a renal physiology lecture series. Fellows also attend seminars in basic science departments. The research mentor, as well as the program director, closely supervise trainees to ensure that the goals of the training program are achieved.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Institutional National Research Service Award (T32)
Project #
5T32DK007659-14
Application #
6800333
Study Section
Special Emphasis Panel (ZDK1-GRB-4 (J3))
Program Officer
Rankin, Tracy L
Project Start
1991-08-01
Project End
2006-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
14
Fiscal Year
2004
Total Cost
$63,392
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Pediatrics
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Sodikoff, J B; Lo, A A; Shetuni, B B et al. (2016) Histopathologic patterns among achalasia subtypes. Neurogastroenterol Motil 28:139-45
Yadlapati, Rena; Gawron, Andrew J; Bilimoria, Karl et al. (2015) Development of quality measures for the care of patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 13:874-83.e2
Joseph, Catherine; Gattineni, Jyothsna; Dwarakanath, Vangipuram et al. (2013) Glucocorticoids Reduce Renal NHE8 Expression. Physiol Rep 1:
Melnick, J Z; Preisig, P A; Alpern, R J et al. (2000) Renal citrate metabolism and urinary citrate excretion in the infant rat. Kidney Int 57:891-7
Melnick, J Z; Preisig, P A; Moe, O W et al. (1998) Renal cortical mitochondrial aconitase is regulated in hypo- and hypercitraturia. Kidney Int 54:160-5
Melnick, J Z; Preisig, P A; Haynes, S et al. (1998) Converting enzyme inhibition causes hypocitraturia independent of acidosis or hypokalemia. Kidney Int 54:1670-4
Bates, C M; Merenmies, J M; Kelly-Spratt, K S et al. (1997) Insulin receptor-related receptor expression in non-A intercalated cells in the kidney. Kidney Int 52:674-81
Melnick, J Z; Srere, P A; Elshourbagy, N A et al. (1996) Adenosine triphosphate citrate lyase mediates hypocitraturia in rats. J Clin Invest 98:2381-7
Brandt, J; Pippin, J; Schulze, M et al. (1996) Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 49:335-43
Pichler, R H; Bassuk, J A; Hugo, C et al. (1996) SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. Am J Pathol 148:1153-67

Showing the most recent 10 out of 13 publications